- Home
- NMIH vs KNSA Comparison
NMIH vs KNSA Comparison
Compare NMIH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | KNSA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NMIH | KNSA |
|---|---|---|
| Price | $41.41 | $42.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $42.20 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 402.8K | 376.3K |
| Earning Date | 02-05-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.56 | N/A |
| EPS | ★ 4.79 | 0.47 |
| Revenue | ★ $692,208,000.00 | $597,973,000.00 |
| Revenue This Year | N/A | $62.63 |
| Revenue Next Year | $4.79 | $29.93 |
| P/E Ratio | ★ $8.65 | $89.97 |
| Revenue Growth | 8.86 | ★ 55.68 |
| 52 Week Low | $31.90 | $17.82 |
| 52 Week High | $43.20 | $44.42 |
Technical Indicators
Market Signals| Indicator | NMIH | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 68.42 | 54.82 |
| Support Level | $40.66 | $40.77 |
| Resistance Level | $41.87 | $44.42 |
| Average True Range (ATR) | 0.81 | 1.28 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 83.00 | 47.14 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.